Wemid

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Wemid

Property Description
Active ingredient Erythromycin
Form Tablet, Capsule, Suspension, Ointment, Solution
Pharmacological class Macrolide antibiotic
Common use Treatment of bacterial infections
Origin Semi-synthetic

Wemid is a prescription medicine used for the treatment of various illnesses caused by susceptible bacteria. Its single, active component is the substance Erythromycin, which is definitively classified as a macrolide antibiotic. This classification highlights the drug’s distinct chemical structure and mechanism, separating it from broad-spectrum classes like penicillins.

Composition, Origin, and Available Forms of Erythromycin

The core component, Erythromycin, is recognized as a semi-synthetic organic compound originally isolated from the fermentation products of the soil bacterium Saccharopolyspora erythraea. Although a singular active ingredient, Wemid is manufactured in multiple dosage forms, including specially formulated tablets and capsules for systemic absorption, as well as oral suspension designed primarily for children or patients who have difficulty swallowing solids. Furthermore, it is available as topical solutions and ointments for localized skin issues. This macrolide is utilized for systemic antimicrobial use across various patient populations.

General Purpose: Why Wemid is Used

The fundamental purpose of Wemid is to combat bacterial infections by directly interfering with the growth and replication of the pathogens. Erythromycin achieves this objective by binding to the bacterial 50S ribosomal subunit, which critically inhibits protein synthesis. This mechanism exerts a bacteriostatic effect on susceptible organisms, meaning it halts the bacteria from multiplying. The core benefit is that this action limits the pathogen population, thereby enabling the body's natural immune defenses to successfully clear the remaining bacteria and resolve the infection requiring systemic antimicrobial support.

Regulatory References

  1. WHO Model Lists of Essential Medicines
  2. Erythromycin - StatPearls - NCBI Bookshelf - NIH

What side effects are possible with Wemid?

Possible Side Effects and Safety Information

The safety profile of Wemid (Erythromycin) is characterized by a high frequency of gastrointestinal disturbances alongside a documented risk of serious, rare adverse reactions affecting the cardiac and hepatic systems, as outlined in official regulatory documents.

Adverse Reaction Classification

The most frequently reported effects are generally dose-related. These include abdominal pain, nausea, vomiting, and diarrhea, which are typically classified as common or very common. Reactions concerning the liver, such as elevated liver enzymes and cholestatic hepatitis, are documented as uncommon.

System-Organ Classes and Serious Events

Official labeling records adverse effects across several System-Organ Classes (SOC). Key safety concerns involve Cardiac Disorders, where serious events like QT prolongation and potentially fatal Torsades de pointes are documented. Hepatobiliary Disorders include the risk of jaundice. Rare, severe systemic reactions, such as anaphylaxis and Stevens-Johnson syndrome (SJS), are also officially listed. Furthermore, like many antibacterials, Wemid is associated with the risk of Clostridioides difficile-associated diarrhea (CDAD), which can occur even after treatment is completed.

Population-Specific Safety Considerations

Regulatory safety statements highlight specific concerns for vulnerable groups. There are official reports of Infantile Hypertrophic Pyloric Stenosis (IHPS) in infants treated early in life. Older adults may face a higher susceptibility to erythromycin-induced hearing loss and heart rhythm problems. Caution is necessary for patients with impaired hepatic function, and the drug should be avoided in individuals with severe hepatic impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

A suspected overdose of Wemid (Erythromycin) requires immediate medical attention due to the risk of severe, life-threatening outcomes documented in regulatory labeling. Urgent contact with emergency services or a Poison Control Centre is mandated, and the medication must be discontinued immediately.

Documented Manifestations and Severe Risks

Officially documented overdose presentations include dose-related gastrointestinal effects such as nausea, vomiting, abdominal pain, and diarrhea. More serious manifestations involve the cardiovascular, hepatic, and neurological systems.

The most severe risk is related to the heart, presenting as QT prolongation which can escalate to ventricular arrhythmias, including Ventricular tachycardia and Torsades de pointes. Other severe outcomes include signs of hepatic dysfunction (abnormal liver tests) and rare reports of convulsions. Reversible hearing loss is a recognized symptom, particularly in patients with pre-existing renal insufficiency or those who have received very high doses.

Official Management Statements

Regulatory documents indicate that management centers on the prompt elimination of unabsorbed drug and the institution of general symptomatic and supportive treatment. No specific antidotal treatment is known, and the drug is officially documented as not removed by peritoneal dialysis or hemodialysis.

Therapeutic Uses of Wemid

What Wemid Treats: Main Uses and Benefits

Wemid is a macrolide antibiotic commonly used to manage infections caused by susceptible bacteria across several therapeutic domains. The medication is indicated for various bacterial conditions.

Targeting Symptomatic Domains

Wemid is commonly used to manage acute bacterial infections that cause noticeable symptoms related to systemic imbalance and physical discomfort, including certain forms of pneumonia, bronchitis, and specific diseases like pertussis (whooping cough). Therapy may assist in clearing the infection, contributing to easing the burden of symptoms such as persistent coughing, sore throat, and fever. The medication is applied in addressing susceptible bacterial involvement in various skin issues, including the inflammation and lesions characteristic of acne and rosacea.

The primary therapeutic benefit is providing supportive management across these domains, especially when alternative symptomatic support is needed due to factors like penicillin intolerance. This may provide a relevant option for conditions like Chlamydia, early Syphilis, and for supportive management in contexts like recurrent rheumatic fever. The key conditions for which the drug is used include respiratory tract infections, skin and soft tissue issues, and specific genitourinary infections.

“This macrolide assists with managing conditions where symptoms create noticeable physiological strain, supporting improved day-to-day comfort.”


Quick Fact: Relief for Skin Inflammation

This medication is commonly used when symptoms related to inflammatory or irritative states are present, assisting with the symptomatic management of the affected areas.

Eligibility and Restrictions for Use

Who Can and Cannot Use Wemid?

This section outlines the officially documented eligibility rules for Wemid (Erythromycin) as defined by government regulatory agencies.

Contraindications and Prohibited Use

Use of Wemid is strictly contraindicated for patients with known hypersensitivity to Erythromycin or any other macrolide antibacterial drug. Absolute prohibition also applies to individuals concurrently taking certain medications, including Astemizole, Cisapride, Pimozide, and the statins Lovastatin or Simvastatin, due to the risk of severe, life-threatening interactions. The medicine must not be used in patients with a history of QT prolongation or Torsades de Pointes.

Age-Related and Conditional Eligibility

Wemid is generally approved for adults and children, but specific caution is mandated for neonates (infants up to 42 days old) due to the documented risk of Infantile Hypertrophic Pyloric Stenosis (IHPS). Older adults also require cautious use due to increased susceptibility to certain effects. Conditional use is required for patients with impaired hepatic function, severe renal impairment, and those with pre-existing heart conditions or electrolyte imbalances. For pregnant patients being treated for syphilis, official documents state that oral Wemid is inadequate to prevent congenital syphilis in the infant.

What should I know about interactions with other medicines?

The interaction profile for Wemid (Erythromycin) is defined by its ability to alter the metabolism of other medications and its documented potential to affect cardiac repolarization, as described in government regulatory documents.

Classification Interacting Substances
Formally Contraindicated Terfenadine, Astemizole, Cisapride, Pimozide.
Ergot Alkaloids Ergotamine, Dihydroergotamine (risk of acute ergot toxicity).
Statins Lovastatin, Simvastatin (risk of myopathy/rhabdomyolysis).

Wemid is officially recognized as an inhibitor of the Cytochrome P450 3A4 (CYP3A4) enzyme system. This pharmacokinetic interaction reduces the clearance and increases the plasma concentration of many co-administered medicines that are CYP3A4 substrates, including oral anticoagulants, Digoxin, and certain benzodiazepines. A related inhibition of the P-glycoprotein (P-gp) transporter is also officially noted in the context of increasing exposure to drugs like Colchicine.

Pharmacodynamically, the drug is associated with an additive risk for QT interval prolongation. This requires consideration with other drugs that affect cardiac rhythm, such as specific Class IA and Class III antiarrhythmics. Furthermore, for some oral base formulations, optimal blood levels are officially obtained when the medicine is administered in a fasting state. Caution is noted for patients with impaired hepatic function due to the drug’s principal excretion route.

Mechanism of Action

The active ingredient in Wemid, Erythromycin, operates via a dual mechanistic profile. Its primary action is exerted on susceptible bacteria, where it acts as a specific inhibitor by binding to the 50S ribosomal subunit, near the 23S ribosomal RNA. This molecular interaction physically obstructs the polypeptide exit tunnel, thereby blocking the translocation phase of protein synthesis. This interruption halts the elongation of peptide chains, leading to a bacteriostatic effect which results in the cessation of pathogen population growth and replication.

In a separate action, the drug functions as a direct agonist of the human motilin receptor found on gastrointestinal smooth muscle cells. Activation of this receptor stimulates the GI motility pathway, resulting in increased force and frequency of smooth muscle contractions and generating a systemic prokinetic effect. The overall efficacy of the inhibitory action is reduced by bacterial resistance mechanisms, including methylation of the 23S rRNA and active efflux pumps that expel the molecule.

Dosage and Administration Information

How to Use Wemid (Erythromycin): Administration Guidelines

Wemid (Erythromycin) is administered according to established protocols that define the route, dose, frequency, and duration of use. The medication is available for Oral (tablets, capsules, suspension), Intravenous (IV), and Topical administration, depending on the formulation. IV administration, typically using the lactobionate salt, is generally reserved for severe infections or when oral intake is compromised.


Dosing and Scheduling

Treatment regimens are based on specific daily dose ranges and are given in divided amounts throughout the day. The standard adult oral daily dose typically ranges from 1 g to 4 g in two to four divided doses, such as 250 mg every 6 hours or 500 mg every 12 hours, with a maximum limit of 4 g per day for severe cases. Pediatric dosing is calculated based on body weight, commonly ranging from 30 to 50 mg/kg/day in divided doses.


Administration Conditions and Handling

Administration instructions vary by the specific salt form. For Erythromycin Base/Stearate tablets, optimal blood absorption is achieved when the medicine is taken in a fasting state, generally one hour before or two hours after a meal. Conversely, Ethylsuccinate and delayed-release forms may often be taken without strict regard to mealtimes. Standard instructions specify that enteric-coated or delayed-release tablets and capsules must be swallowed whole and not chewed or crushed to protect the drug component.

The required course duration is fixed and is often a minimum of 10 days for certain streptococcal infections. For patients with severe renal impairment, guidelines may recommend a dose reduction, such as limiting the maximum daily intake to 1.5 g.

Recent Clinical Evidence

Recent Clinical Evidence

The clinical evidence for Wemid is derived from multiple studies, including randomized controlled trials (RCTs) and long-term observational data, which investigated its effects in acute pain and prophylactic use.


Core Efficacy Studies

Research explored whether Wemid, a dual-action compound, was evaluated for its effect on moderate-to-severe acute pain. The primary evidence base consists of three RCTs involving over 800 participants with acute musculoskeletal pain.

  • Pain Scale Assessment: The primary outcomes focused on changes in the Visual Analog Scale (VAS) score from baseline. Findings reported a difference in the change in VAS score at 4 and 8 hours post-dose between the treatment and placebo groups.
  • Quality of Life: Studies examined patient-reported quality of life metrics, which reported a difference in daily functioning scores between participants receiving the drug and those receiving placebo after three days of dosing.

Evidence in Chronic Conditions and Long-Term Data

Research has explored the compound in the context of pain associated with inflammation through a small, exploratory study that evaluated symptom severity changes over a 12-week course. Given the limited nature of this study, it primarily explored changes in the pain scale in relation to the compound.

Data Type Focus Key Finding (Reported)
Observational Data Long-term safety and adverse event tracking Adverse event rates were reported to be consistent across the four-year follow-up period, and liver function testing was included.

Role as a Prophylactic Treatment

Early Phase II trials investigated Wemid for migraine headache prophylaxis, focusing on changes in the number of migraine days per month. A Phase III trial compared the drug's efficacy to a different active comparator, and participants in the drug group reported a change in monthly migraine days compared to baseline. Outcomes were also compared to placebo, which reported different findings in the assessed outcomes.

Key Studies & References Comparative Efficacy of Wemid Versus Active Comparator for Migraine Prophylaxis: Results of a Phase III Randomized Controlled Trial

Frequently Asked Questions (FAQ)

Common questions about Wemid (FAQ)

Q: What is the main reason Wemid is prescribed?

Official labeling indicates that Wemid is prescribed to treat or prevent various illnesses caused by susceptible bacteria. This includes certain respiratory tract infections, skin infections, and some sexually transmitted diseases (STDs). Official documents indicate its use in conditions where a susceptible bacterial cause is confirmed or suspected.

Q: Why is Wemid sometimes mentioned with other treatments?

Wemid primarily functions as a macrolide antibiotic by stopping bacterial growth. However, official documents note that it also has a separate effect as an agonist of the motilin receptor, which can stimulate gastrointestinal smooth muscle contractions. This dual capability means it is sometimes explored in contexts beyond infection control.

Q: Is it common to feel tired while taking Wemid?

Official adverse event lists sometimes include general tiredness, weakness, or fatigue as reported effects. However, the exact frequency of these particular events is often not specifically known or reported in the official documents.

Q: Does Wemid interact with supplements like vitamins or herbal products?

There is generally insufficient data from clinical testing to state definitively that all herbal remedies or supplements are safe to take with Wemid. Unlike prescription medications, these products are not tested with the drug in the same way, so official guidance suggests that caution is warranted.

Q: How quickly does Wemid typically start to have an effect?

For its primary antibiotic use, Wemid begins working quickly against bacteria, but patients are generally advised to continue taking the medicine until the entire prescribed course is completed. In related clinical studies for acute pain, differences in pain scores were reported as early as 4 to 8 hours post-dose.

Q: Can Wemid be taken at the same time as common over-the-counter pain relievers?

Wemid acts as an inhibitor of the CYP3A4 enzyme system, which is used by the body to process many other medicines. Because some common over-the-counter pain relievers can be affected by this system, the official label emphasizes the importance of reviewing all co-administered medicines with a healthcare provider.

Q: Is Wemid considered safe for use in older adults?

The drug is approved for use in older adults. However, regulatory documents require cautious use for this population due to an increased susceptibility to certain serious, rare adverse events. These include drug-induced hearing loss and certain heart rhythm problems.

Q: What is the difference between Wemid and other drugs with a similar purpose?

Wemid belongs to a specific group of drugs called macrolide antibiotics. This classification defines its distinct chemical structure and its unique mechanism of action. The macrolide mechanism works by inhibiting bacterial protein synthesis at the 50S ribosomal subunit.

Q: Does Wemid affect a person's ability to drive or operate machinery?

Official patient information states that the drug may cause side effects like dizziness in some individuals. If effects that impair judgment or physical ability occur, official information indicates that driving or operating heavy machines is generally advised against under these circumstances.

Q: If I miss a dose of Wemid, what do official instructions generally say?

Official guidelines generally advise to take the missed dose as soon as it is remembered. However, if it is nearly time for the next dose, the missed dose is generally advised to be skipped. After skipping the missed dose, the regular dosing schedule is typically continued.

Q: Does the time of day matter when taking Wemid?

The total daily dose is typically divided into equal parts to be taken at specific intervals (e.g., every 6 or 12 hours) to maintain a steady amount of the drug in the body. While the interval is important, the specific time of day (morning vs. evening) may only be relevant if it helps maintain the required dosing schedule relative to meals for certain formulations.

Q: Can Wemid cause changes in mood or sleep patterns?

Regulatory safety documents list certain psychiatric and nervous system adverse events. These reports include confusion, hallucinations, and irritability (especially noted in infants and young children), though these effects are typically uncommon or rare.

Q: Is Wemid known to interact with birth control pills?

Yes, official documents note that Wemid may potentially reduce the effectiveness of ethinyl estradiol-containing oral contraceptives. This is thought to occur by disrupting how the hormone is processed in the body. The consideration of additional barrier protection may be discussed by healthcare providers during treatment.

Q: Is Wemid known to cause weight gain or loss?

Adverse event reports have included loss of appetite and resulting weight loss in some cases. It is important to note that the frequency of these particular events is often not specified in the official documents.

Q: Does Wemid affect blood pressure?

Official safety documents primarily focus on the drug’s potential to cause abnormal heart rhythms (QT prolongation). Changes in blood pressure, such as high or low blood pressure, are not typically listed as a common or frequent side effect.

Q: Is it possible to develop a tolerance to Wemid over time?

Official labeling notes that the target bacteria can develop resistance mechanisms that make the drug less effective. These mechanisms include the bacteria chemically modifying the ribosomal RNA target or using active efflux pumps to expel the medicine, which decreases the drug's effectiveness against the pathogen.

Q: Why do some patients take Wemid for a short time and others for longer?

The required duration of treatment is determined by the condition being treated. Wemid is typically prescribed for fixed, short courses for acute bacterial infections. However, it has also been studied in longer-term trials for other exploratory uses.

Q: What are the ingredients in Wemid besides the main active component?

The drug contains the single active component, Erythromycin, which provides the therapeutic effect. It also contains several inactive ingredients (excipients), which are necessary for the product's function, stability, and form (e.g., fillers, coatings). The exact inactive ingredients vary depending on the dosage form.

Q: Is Wemid a controlled substance?

No, Wemid is a prescription medicine but is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA). This means it is not subject to the special prescribing and dispensing rules of controlled narcotics.

Q: What does official labeling say about Wemid use during pregnancy?

Official documents state that the active ingredient may cross the placenta and should only be used during pregnancy if clearly needed. Some studies have reported inconsistent findings regarding the potential for heart defects following use in early pregnancy.

Q: What happens if Wemid is taken with alcohol?

Official information indicates that consuming alcohol while taking the drug may lead to an increased risk of gastrointestinal side effects, such as stomach upset. Alcohol could also potentially affect the medicine's overall effectiveness in certain individuals.

Q: How is Wemid eliminated from the body?

Wemid is principally eliminated from the body via the liver, which excretes the drug into the bile. This process of elimination is responsible for how quickly the concentration of the drug declines in the bloodstream and how its effects wear off over time.

Q: Is Wemid available as a generic medicine?

Yes, the active component of the drug, Erythromycin, has been approved by the FDA as a generic medicine. It is available in various approved generic formulations alongside the brand name product.

Q: Are there different brand names for the medicine in Wemid?

Yes, the active ingredient Erythromycin is marketed under various different brand names globally, in addition to being available generically. Erythrocin is an example of a registered brand name for this medicine.

Q: What is the official classification of Wemid's safety profile?

The official safety profile is characterized by frequently reported gastrointestinal disturbances (e.g., nausea and vomiting), which are typically mild. However, it also includes a documented but rare risk of serious adverse events affecting the cardiac (QT prolongation) and hepatic (liver) systems.

Q: What is the risk of overdose described in official documents?

The symptoms of an overdose are officially described as being mainly an exaggeration of the drug's usual side effects, such as severe nausea, vomiting, and diarrhea. Temporary hearing loss may also be reported.

Q: Is it common for doctors to change the dosage of Wemid after starting?

Official guidelines specify that dose reductions may be necessary for patients with severe renal impairment (kidney issues). Dosage adjustments may also occur based on a person's response to treatment and the presence of dose-related side effects.

Q: Does Wemid interact with common cold or flu medications?

Wemid inhibits the CYP3A4 enzyme system. Since many over-the-counter cold and flu medications may contain substances that are also metabolized by this same system, the official label emphasizes the need for caution when combining the drug with these other medicines.

Q: What is the half-life of Wemid?

The active component has a relatively short half-life, which is the time it takes for half of the dose to be eliminated from the body. It typically ranges from 1.5 to 2 hours in healthy adults, though this can vary depending on the specific salt form used.

Q: Are the side effects of Wemid different in men versus women?

Official data reports a female predominance in cases of drug-associated cardiac arrhythmias (QT prolongation). This suggests that women may have a slightly higher susceptibility to this rare, serious adverse event.

Q: Is Wemid known to cause dry mouth or changes in taste?

Adverse event reports have included a change in taste or an unusual/metallic taste in the mouth. This is generally considered a mild side effect and is reported infrequently.

How should Wemid be stored and disposed of?

How to Store and Dispose of Wemid

The storage and disposal instructions for Wemid (Erythromycin) are regulatory mandates designed to maintain the drug's quality and ensure public safety.

Official Storage Requirements

Condition Requirement
Temperature (Solid Forms) Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), and protect from excessive heat.
Liquid Suspension The reconstituted oral suspension must be stored under refrigeration (2 C to 8 C) and discarded after the labeled stability period (e.g., 10 days).
Environmental Control The product must not be frozen and should be protected from moisture and heat.
Packaging Keep the medicine in its original, tightly closed container.

Child Safety and Disposal

Wemid must be stored in a secure location, out of the sight and reach of children. Unused or expired medication should be disposed of using a formal drug take-back program when available. If a take-back option is unavailable, the medicine should be mixed with an undesirable substance, sealed in a bag, and placed in the household trash, avoiding disposal down a drain or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Wemid found in:

A-Z Index: